Introduction to Samin Darou Iranian Company

Samin Darou Iranian (Private Joint Stock Company) is one of the emerging players in Iran’s Active Pharmaceutical Ingredients (API) industry. The company was registered in December 2015 and, after fully equipping its factory based on GMP principles, officially commenced operations in October 2019.

---

Scope of Activities and Production Lines

• Production of Active Pharmaceutical Ingredients (API): Samin Darou has localized the supply chain of vital raw materials for the domestic market by relying on up-to-date process technologies.

• Pellet Production Unit: This unit was launched in the second half of 2020 and became operational in the second half of 2021; it enables the formulation of controlled-release pellet dosage forms.

• Registered know-how for five key APIs:

  • Tamsulosin 0.2%

  • Pantoprazole Sodium 15%

  • Diclofenac Sodium 45%

  • Esomeprazole Magnesium 22.5%

  • Omeprazole 8.5% (IXPO: Online Health Catalog)

---

Infrastructure and Geographic Location

The Samin Darou factory is located in the Kaveh Industrial City (Markazi Province); its proximity to the country’s largest pharmaceutical hub provides significant logistical and networking advantages for supply and distribution. The company’s headquarters are located in Tehran, on Sadr Expressway. (Kaveh Industrial City)

---

Standards and Quality Requirements

• GMP and national requirements of the Food and Drug Administration: Facility design, ventilation systems, cross-contamination control, and process documentation have been implemented according to current EU and WHO standards. (SAMIN DAROU)

• Continuous quality monitoring: The Quality Assurance (QA) and Quality Control (QC) units, equipped with modern chromatography and spectroscopy devices, evaluate raw materials and final products at every stage.

---

Vision and Mission

With the goal of reducing foreign currency dependency in supplying high-consumption APIs, Samin Darou aims to expand its product portfolio to more than 15 APIs by 2027 and simultaneously start regional exports to CIS and Middle Eastern markets. Continuous participation in specialized exhibitions—such as Iran Pharmex—is also part of the company’s global marketing and networking strategy. (SAMIN DAROU)

---

Conclusion

In less than a decade, Samin Darou Iranian has succeeded in gaining a significant position in the country’s pharmaceutical supply chain by investing in API production technologies, GMP standards, and pellet manufacturing units. The company’s focus on formulation innovation and expanding its product portfolio draws a clear vision for becoming one of the leading API producers in the region.